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Multi-drug resistance (MDR) of cancer cells severely limits therapeutic outcomes. A proposed mechanism for MDR
involves the efflux of anti-cancer drugs from cancer cells, primarily mediated by ATP-binding cassette (ABC) mem-
brane transporters including P-glycoprotein. This article reviews the recent progress of using active ingredients,
extracts and formulae from Chinese medicine (CM) in circumventing ABC transporters-mediated MDR. Among the
ABC transporters, Pgp is the most extensively studied for its role in MDR reversal effects. While other MDR reversal
mechanisms remain unclear, Pgp inhibition is a criterion for further mechanistic study. More mechanistic studies
are needed to fully establish the pharmacological effects of potential MDR reversing agents.
Review
Multi-drug resistance (MDR)
Multi-drug resistance (MDR) in cancer chemotherapy
refers to the ability of cancer cells to survive from treat-
ment of a wide range of drugs [1]. In addition to the
MDR induced by drugs in early exposure, the MDR can-
cer cells may subsequently develop cross-resistance to
several unexposed and structurally unrelated chemother-
apeutic agents [2]. Mechanisms of MDR include
decreased uptake of drugs, alterations in cellular path-
ways and increased active efflux of drugs [3-5] (Figure 1).
Overexpression of ATP-binding cassette (ABC) transpor-
ters is one of the most common mechanisms. ABC trans-
porters are large membrane-bound proteins consisting of
two nucleotide-binding domains (NBDs) and two trans-
membrane domains (TMDs) which mediate the active
transport of substrate drugs out of the cell (Figure 2).
Overexpression of the three major ABC transporters, i.e.
P-glycoprotein (Pgp), multidrug-resistance-associated
protein 1 (MRP1) and breast cancer resistance protein
(BCRP/ABCG2) is frequently observed in cancer cell
lines selected with chemotherapeutic drugs [6] and criti-
cal to clinical drug resistance [7].
P-glycoprotein (Pgp)
P-glycoprotein (Pgp) [8], which is also referred to as
ABCB1 and MDR1, is the most studied ABC transpor-
ter. Pgp transports a wide range of chemotherapeutic
agents including the anthracyclines, vincas, taxanes, eto-
poside and mitoxantrone [6]. Pgp is expressed in various
tissues in the body. Remarkably high expression can be
found in endothelial cells of capillary blood vessels in
the brain as well as other organs including intestines,
testes and skin [9,10]. Pgp expression is often detected
in renal carcinoma, colon carcinoma, adrenal carcinoma
and teratocarcinoma [9]. Substrate drugs can bind to
Pgp through multiple binding sites, thereby allowing
flexibility in the mechanism of transport [11,12].
Multidrug-resistance-associated protein 1 (MRP1)
The second major MDR transporter, multidrug-resis-
tance-associated protein (MRP), was first discovered in a
doxorubicin-selected lung cancer cell line [13]. A mem-
ber of the ABCC subfamily, MRP1 is encoded by the
ABCC1 gene [14]. Physiologically, MRP1 tends to pump
drugs into the body, rather than excreting them into the
bile, urine or gut [15,16]. MRP1 was highly expressed in
skeletal muscles [17]. Overexpression of MRP1 is in
cancer types such as lung, colon and various forms of
leukaemia [18].
Breast cancer resistance protein (BCRP/ABCG2)
Recently, ABCG2 was identified in cancer cell lines
selected with mitoxantrone that do not express Pgp and
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several research groups, it was also named BCRP, ABCP
and MXR [19-21]. ABCG2 is expressed in a range of tis-
sues, most abundantly in the liver and intestinal epithe-
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fied metabolites, toxins and carcinogens [25].
Chinese medicine and MDR
How to tackle the MDR cells in chemotherapy is a
pressing issue in cancer treatments. Verapamil was the
first known Pgp inhibitor to increase the intracellular
concentration of anticancer agents in MDR cells by
binding to Pgp and inhibiting the Pgp-mediated efflux
[26]. It was believed that anticancer drug resistance
could be reversed by drug efflux inhibition. Researchers
developed and tested a range of Pgp inhibitors to
improve the pharmacological effects of chemotherapy in
cancer patients [27-29]. However, none of these Pgp
inhibitors was further developed for clinical use. Many
researchers are looking into Chinese medicine (CM) for
potential MDR reversing agents.
This article reviews some of the recent findings on the
circumvention of ABC transporters-mediated MDR by
various ingredients and extracts of CM and their
formulae based on whether the MDR reversal involved
Pgp alteration.
MDR reversal involving Pgp inhibition
Active ingredients - alkaloids
Tetrandrine, a calcium channel blocker, is a bisbenzyli-
soquinoline alkaloid isolated from the root of Stephania
tetrandra (Fenfangji) [30]. Tetrandrine reversed MDR in
vitro and modulated Pgp-mediated drug efflux [30-33].
A combination of tetrandrine with doxorubicin or vin-
cristine in vitro demonstrated synergistic anticancer
effects [34]. Tetrandrine reduced Pgp expression [35]. In
mice bearing resistant MCF-1/DOX cells, tetrandrine
potentiated the antitumor activities of doxorubicin with-
out significantly increasing toxicity [36]. A synthetic
halogenated form of tetrandrine increased vinblastine
accumulation in a dose-dependent manner in resistant
P388/DOX cell line and prolonged the life-span of
tumour-bearing mice up to 25% without any side effects
[37]. In a recent clinical trial, a combination of
Figure 1 Mechanisms of MDR towards cancer chemotherapeutic drugs. Cancer cells can develop resistance to multiple drugs by various
mechanisms as depicted. Mechanisms include (a) decreased uptake of drug, (b) reduced intracellular drug concentration by efflux pumps, (c)
altered cell cycle checkpoints, (d) altered drug targets, (e) increased metabolism of drug and (f) induced emergency response genes to impair
apoptotic pathway.
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demonstrated antileukaemic effects in 38 patients with
acute myeloid leukaemia [38].
Matrine is a quinolizidine alkaloid from Sophora alo-
pecuroides (Kudouzi). In resistant K562/DOX cell line,
matrine (up to 50 μg/mL, non-toxic) increased the intra-
cellular accumulation of doxorubicin and induced its
apoptotic effects [39]. Matrine enhanced the cytotoxicity
of vincristine in resistant K562/VCR cell line [40]. It was
proposed that matrine circumvented MDR by reducing
Pgp expression [35].
Tetramethylpyrazine is an active alkaloid from Ligusti-
cum chuangxiong (Chuanxiong) and a calcium channel
blocker [41]. In Pgp-overexpressing resistant HL-60/
VCR cell line, tetramethylpyrazine significantly reversed
MDR towards various drugs such as vincristine, duanor-
ubicin and doxorubicin [42]. Tetramethylpyrazine
reduced drug efflux (up to 50%) in Pgp-overexpressing
resistant MCF-7/DOX cell line [43]. When used
together with b-elemene, tetramethylpyrazine exhibited
stronger MDR reversal effects in resistant K562/DOX
cell line [44]. Tetramethylpyrazine decreased Pgp
expression in resistant HepG2/DOX cell line [45]. How-
ever, the reduction in Pgp expression was not univer-
sally observed. For instance, Pgp level was not altered
despite MDR reversal in tetramethylpyrazine-treated
K562/DOX cells [46].
Peimine (also known as verticine) is a cevanine type
isosteroidal alkaloid from the bulbs of Fritillaria thun-
bergii (Zhebeimu) and other Fritillaria species [47,48].
In resistant K562/DOX and HL-60/DOX cell lines, pei-
mine increased intracellular concentration of daunorubi-
cin and reversed MDR probably through inhibition of
Pgp expression [49].
Berbamine is a calcium channel blocker from Maho-
nia fortunei (Shidagonglao). In K562/DOX cell line, ber-
bamine inhibited cell growth by inducing apoptosis in a
dose-dependent manner and reduced Pgp expression
thereby increasing the intracellular concentration of rho-
damine-123 and doxorubicin [50,51]. In MCF-7/DOX
cell line, O-(4-ethoxyl-butyl)-berbamine, a derivative of
berbamine, reversed MDR by enhancing G2/M arrest
and increasing the intracellular accumulation of doxoru-
bicin [52].
Active ingredients - saponins
Ginsenosides are the major active components from
Panax ginseng (Renshen). Ginsenosides are mainly tri-
terpenoid dammarane derivatives. Several ginsenosides,
namely Rg1,R g 3, Re, Rc and Rd inhibited drug efflux
[53]. A combination of purified saponins containing
Rb1,R b 2, Rc, Rd, Re and Rg1 reversed MDR whereas
individual ginsenosides did not produce any effect [54].
Ginsenosides reversed MDR of several chemotherapeutic
drugs such as homoharringtonine, cytarabine, doxorubi-
cin and etoposide in K562/VCR and in a dose-depen-
dent manner in K562/DOX [55]. Pgp expression
decreased but bcl-2 expression remained the same [56].
Rb1 reversed MDR of harringtonolide and vincristine in
K562/HHT and HL60/VCR cell lines respectively
[57,58].
Panax notoginseng (Sanqi) total saponins reversed
MDR of doxorubicin in MCF-7/DOX and K562/VCR
cell lines. The mechanism may be related to the
decrease of Pgp expression [59,60].
Active ingredients - flavonoids
Quercetin is one of the most widely distributed flavo-
noids in natural products including Chinese medicinal
herbs such as Sophora japonica (Huai). Quercetin inhib-
ited the binding of heat shock factor at the MDR1 pro-
moter, thereby decreasing MDR1 transcription and
reducing Pgp expression [61]. Quercetin also inhibited
the overexpression of Pgp mediated by arsenite [62]. In
HL-60/DOX and K562/DOX cell lines, quercetin
enhanced the anticancer sensitivity to daunorubicin and
Figure 2 Proposed drug efflux mechanism for ABC transporters. Substrate and ATP bind to ATP transporters. After ATP hydrolysis, the
substrate is effluxed out of the cell. Phosphate group is released and the substrate is then excreted to extracellular matrix.
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quercetin was probably mediated by its action on mito-
chondrial membrane potential and the induction of
apoptosis. Furthermore, quercetin derivatives rather
than quercetin itself reversed MDR [65]. Quercetin
increased the sensitivity of Pgp-overexpressing KBV1
cell line towards vinblastine and paclitaxel in a dose-
dependent manner. Among many active flavonoids,
quercetin was less potent than kaempferol but more
effective than genistein and daidzein in reversing MDR.
Genistein and daidzein had no effect on Pgp expression
[66]. Although quercetin may be a potential MDR rever-
sing agent, lethal drug-drug interaction between querce-
tin and digoxin has been reported. Quercetin (40 mg/
kg) elevated the peak blood concentration of digoxin
and caused sudden death of tested animals [67].
Curcumin, the major component in Curcuma longa
(Jianghuang), inhibited the transport activity of all three
m a j o rA B Ct r a n s p o r t e r s ,i . e .P g p ,M R P 1a n dA B C G 2
[68]. Curcumin reversed MDR of doxorubicin or dau-
norubicin in K562/DOX cell line and decreased Pgp
expression in a time-dependent manner [69]. Curcumin
enhanced the sensitivity to vincristine by the inhibition
of Pgp in SGC7901/VCR cell line [70]. Moreover, curcu-
min was useful in reversing MDR associated with a
decrease in bcl-2 and survivin expression but an
increase in caspase-3 expression in COC1/DDP cell line
[71]. The cytotoxicity of vincristine and paclitaxel were
also partially restored by curcumin in resistant KBV20C
cell line [72]. Curcumin derivatives reversed MDR by
inhibiting Pgp efflux [72]. A chlorine substituent at the
meta-or para-position on benzamide improved MDR
reversal [72]. Bisdemethoxycurcumin modified from cur-
cumin resulted in greater inhibition of Pgp expression
[73]. Tetrahydrocurcumin, the major metabolite of cur-
cumin, inhibited all three major ABC transporters [74].
Curcumin induced atypical and caspase-independent
cell death in MDR cells [75]. In leukaemic cells collected
from 78 childhood leukaemia patients, curcumin
reduced Pgp expression [76]. A specialized nanoemul-
sion of curcumin is better than conventional solution
form drugs in enhancing the efficiency of drug delivery
into the cells, down-regulating Pgp expression, inhibit-
ing the NFB pathway and promoting apoptotic
response [68,77].
Active ingredients - others
Schizandrins, the active constituents of Schisandra chi-
nensis (Wuweizi), were investigated for their MDR
reversal effects. Schizandrin A was the most potent in
reversing MDR by enhancing apoptosis and down-regu-
lating Pgp and total protein kinase C expression. The
crude extract of Schisandra chinensis reversed the resis-
tance against vincristine in vivo [78]. Deoxyschizandrin
and g-schizandrin, among the nine dibenzo[a,c]
cyclooctadiene lignans examined, enhanced intracellular
drug concentration and induced cell cycle arrest at the
G2/M phase when combined with sub-toxic dosages of
doxorubicin [79]. Gomisin A, on the other hand, altered
Pgp-substrate interaction by binding to Pgp simulta-
neously with substrates [80].
Formulae - injections
’Shengmai Injection’, consisting of Panax ginseng and
Ophiopogon japonicus (Maidong), down-regulated Pgp
expression in peripheral blood lymphocyte membrane.
When used together with oxaliplatin, 5-fluorouracil or
folinic acid, the injection prolonged the survival rate of
colon cancer patients [81]. The injection also enhanced
the efficacy of tamoxifen and nifedipine in combination
therapy [82].
Formulae - powders
’Shenghe Powder’, consisting of Panax ginseng, Scoro-
phularia ningpoensis (Xuanshen) and Atractylodes
macrocephala (Baizhu), increased the intracellular con-
centration of vincristine in resistant SGC-7901/VCR cell
line, possibly due to the induction of apoptosis and
down-regulation of Pgp and bcl-2 expression [83].
’Modified Sanwubai Powder’, consisting of herbs such
as Croton tiglium (Badou), Platycodon grandiflorum (Jie-
geng) and Fritillaria thunbergii,i n d u c e da p o p t o s i si n
SGC-7901 cell line and down-regulated the gene expres-
sions of p53, bcl-2, rasP21CD44 and Pgp [84].
Formulae - others
Three herbal extracts used to treat diseases other than
cancer, namely Ams-11, Fw-13 and Tul-17, greatly
enhanced the efficacy of vincristine both in vitro and in
vivo and reversed MDR in a dose-dependent manner.
Tul-17 inhibited Pgp expression [85].
Oil emulsion from Brucea javanica (Yadanzi) reversed
MDR when used together with other chemotherapeutic
drugs such as vincristine, doxorubicin, cisplatin, mito-
mycin C, 5-fluorouracil or etoposide, probably due to
down-regulation of Pgp expression or inhibition of
TOPO II or both [86,87].
’Sangeng Mixture Decoction’, consisting of Reynoutria
japonica (Huzhang), Actinidia arguta (Mihouligen) and
Geum aleppicum (Shuiyangmeigen), reversed MDR of
doxorubicin via down-regulation of Pgp expression [88].
FFTLG, a formula containing Actinidia arguta,
reversed MDR in K562/DOX cell line by increasing the
intracellular doxorubicin concentration [89].
R1, consisting of Ligusticum chuanxiong, Curcuma
longa and Millettia dielsiana (Jixueteng), enhanced the
anticancer activities of doxorubicin in MCF-7/DOX via
down-regulation of Pgp expression [90,91].
When tested with doxorubicin, 5-fluorouracil and
epirubicin in HepG2/DOX cell line, Ganai-1, a commer-
cial product, reversed MDR via down-regulation of Pgp
expression [92]. Another commercial product,
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line and reversed MDR of doxorubicin [93]. An umbili-
cal plaster used with 5-fluorouracil, mitomycin C or cis-
platin reversed MDR via down-regulation of Pgp
expression [94].
MDR reversal not related to Pgp alteration
Active ingredients - alkaloids
Dauricine is a bisbenzylisoquinoline alkaloid isolated
from the root of Menispermum dauricum (Bianfuge) as
a calcium channel blocker. Dauricine reversed vincris-
tine resistance in MCF-7/DOX cell line [95]. However,
dauricine did not alter Pgp expression in K562/DOX
cell line [96]. Moreover, dauricine enhanced the cyto-
toxic effects of doxorubicin in HL60/HAR cell line with-
out increasing the intracellular concentration of
doxorubicin or inhibiting Pgp overexpression [97].
Daurisoline, a structural analogue of dauricine, is also
a calcium channel blocker isolated from the root of
Menispermum dauricum. Both dauricine and daurisoline
sensitized MCF-7/DOX cell line towards doxorubicin
and vincristine in a dose-dependent manner [98]. The
MDR reversal effects of dauricine and daurisoline are
comparable to those of verapamil and both alkaloids do
not cause cardiovascular adverse effect [99].
Active ingredients - saponins
20(S)-Ginsenoside Rg3, one of the active ginsenosides
from Panax ginseng, restored the sensitivity of resistant
KBV20 cell line to various anticancer drugs, including
vincristine, doxorubicin, etoposide and colchicine in a
time-and dose-dependent manner. This ginsenoside
competitively inhibited the binding of substrate drugs to
Pgp and its binding affinity to Pgp was remarkably
higher than that of verapamil. In contrast to the dose-
dependent effects in vitro, 20(S)-ginsenoside Rg3
increased animal life span in an in vivo MDR model in a
dose-independent manner [53].
Active ingredients - flavonoids
Paeonol is a weak calcium channel blocker isolated from
the root of Paeonia suffruticosa (Mudan). In K562/DOX
cell line, paeonol showed positive MDR reversal effect
towards doxorubicin, daunorubicin, vincristine and vin-
blastine without modulating Pgp expression [100]. In
parental K562 cells, paeonol induced apoptosis in a
time-and dose-dependent manner [101].
Formulae - injections
’KLT Injection’ consisting of the extract of Coix
lacryma-jobi (Yiyi) enhanced the anticancer activities of
paclitaxel and docetaxel and reversed MDR in a dose-
dependent manner [102].
Formulae - others
’Siwu Mixture’, consisting of Paeonia lactiflora
(Shaoyao), Rehmannia glutinosa (Dihuang), Angelica
sinensis (Danggui) and Ligusticum chuanxiong, reversed
doxorubicin MDR without altering Pgp expression in
K562/DOX cell line [103].
Other mechanisms
Active ingredients
Pseudolaric acid B, a major active component of Pseudo-
larix kaempferi (Jinqiansong), reversed MDR in vitro
and in vivo and induced apoptosis via cell cycle arrest at
G2/M phase. In either resistant cell line or nude mice
model, pseudolaric acid B circumvented MDR associated
with Pgp overexpression [104].
Salvinal, isolated from Salvia miltiorrhizae (Danshen),
induced apoptosis and inhibited tubulin polymerization
in various cancer cell lines, including the Pgp and MRP-
overexpressing MDR cells [105].
A study on 22 compounds from CM herbs found that
homoharringtonine, artesunate and bufalin from Cepha-
lotaxus hainanensis (Hainancufei), Artemisia annua
(Qinghao) and Bufo marinus, B. viridis (Chanchu)
respectively exhibited active MDR modulation [106].
Moreover, other compounds such as jatrorrhizine, indir-
ubin, rhynchophylline [107], arsenic trioxide [108,109],
psoralen [110,111], oridonin [99,112], b-elemene
[113,114] also showed MDR reversal effects.
Extracts
Nine out of 20 extracts of Ganoderma species including
G. lucidum (Lingzhi) were cytotoxic and induced apop-
tosis similar to etoposide and doxorubicin which are
commonly used in chemotherapy. In etoposide-selected
resistant cell line H69, G. lucidum extract increased the
sensitivity to etoposide and doxorubicin significantly,
possibly due to increased intracellular DNA fragmenta-
tion and caspases 3 and 9 activities [115]. Moreover,
extracts of Glycyrrhiza glabra (Gancao), Hedyotis diffusa
(Baihuasheshecao) and Rheum palmatum (Dahuang)
reversed MDR by increasing the intracellular concentra-
tion of daunorubicin in SGC7901/VCR cell line [116].
Formulae
’Ganli Injection’, consisting of matrine and tetramethyl-
pyazine hydrochloride, reversed MDR by increasing the
sensitivity of 5-fluorouracil and the intracellular concen-
tration of doxorubicin in BEL-7402/5-FU cell line [117].
’Bushen Huayu Jiedu Formula’, consisting of Cinnamo-
mum cassia (Rougui), Psoralea corylifolia (Buguzhi) and
Rheum palmatum, was tested in A549/DDP cell line
and S180 tumour-bearing mice. In vitro, the formula
significantly increased the intracellular concentration of
cisplatin at high doses and inhibited the activity of cal-
cium channel and LRP-56 expression at both high and
low doses. In vivo, the formula improved the serum con-
centration, reduced the inflow and the release of Ca
2+
and inhibited the LRP gene expression [118,119].
Four CM formulae, namely Glycyrrhiza glabra
(GLYC), Hedyotis diffusa (OLEN), a formula consisting
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grong), Rabdosia rubescens (Donglingcao) and Zanthox-
ylum nitidum (Liangmianzhen) (SPES), and a formula
consisting of eight herbs including Serenoa repens
(Juyezhong), Scutellaria baicalensis (Huangqin), Panax
ginseng and Glycyrrhiza glabra (PC-SPES) were cyto-
toxic to cancer cell lines in a dose-dependent manner.
SPES, PC-SPES, OLEN decreased the bcl-2 gene expres-
sion and were pro-apoptotic, while GLYC was pro-
necrotic without altering the over-expression of bcl-2 in
MDR cells. Furthermore, OLEN, SPES and PC-SPES
exhibited similar pharmacological effects to etoposide
and vincristine [120].
Many MDR reversing alkaloids are also calcium-chan-
nel blockers probably because of (1) their structural
similarity and (2) inhibition of ABC transporters by the
decrease in intracellular calcium concentration. Future
research is warranted for potent MDR inhibitors without
other pharmacological activities.
Over-expression of ABC transporters and enhanced
drug efflux are the causes for MDR. Among the ABC
transporters, Pgp is the most extensively studied for its
role in MDR reversal effects. While other MDR reversal
mechanisms remain unclear, Pgp inhibition is a criterion
for further mechanistic study. This article summarises
these proposed mechanisms (Additional file 1).
Conclusion
As some CM active ingredients reverse MDR by directly
inhibiting growth and inducing apoptosis in cancer cells,
the Pgp-inhibiting CM active ingredients may also be
cytotoxic to cancer cells. Future studies should explore
not only the MDR reversal effects but also the cytotoxic
effects of various CM active ingredients.
Additional material
Additional file 1: Proposed mechanisms for MDR reversal by the
tested Chinese medicinal herbs. The herbs are grouped into three
categories, namely active ingredients, extracts and formulae. Pgp
involvement is particularly considered: (+) inhibition on Pgp; (-) no effect
on Pgp.
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